New hope for High-Risk myeloma: early use of Immune-Boosting drugs

NCT ID NCT05849610

Ongoing Disease control Sponsor: PETHEMA Foundation Source: ClinicalTrials.gov ↗

First seen May 12, 2026 · Last updated May 12, 2026

Summary

This study tests two new drug combinations (teclistamab plus daratumumab and talquetamab plus daratumumab) in 30 people with newly diagnosed high-risk multiple myeloma. The goal is to see if these treatments can make the cancer undetectable after initial therapy. Participants will receive the drugs early in their treatment plan to try to achieve the best possible remission.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK DE NOVO MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Clinica Universidad de Navarra

Pamplona, Spain
Complejo Hospitalario Santiago (CHUS)

Santiago de Compostela, Spain
H. Universitario Marqués de Valdecilla

Santander, Spain
Hospital Clinic i Provincial de Barcelona

Barcelona, Spain
Hospital Doce de Octubre

Madrid, 28041, Spain
Hospital Germans Trials i Pujol

Badalona, Spain
Hospital Universitari i Politecnic la Fe

Valencia, Spain
Hospital Universitario de Salamanca

Salamanca, Spain
Hospital Virgen de la Arrixaca

Murcia, Spain
Hospital Vírgen del Rocío

Seville, Spain

Conditions

Explore the condition pages connected to this study.

HIGH-RISK DE NOVO MULTIPLE MYELOMA